SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – When it comes to contact lens wear, open communication between eye care providers and patients is essential for achieving lasting satisfaction and optimal eye health. Alcon, a global leader in eye care, recognizes the importance of this relationship and emphasizes the value of in-depth discussions to address patient needs and concerns.

Understanding Patient Priorities

Eye care professionals (ECPs) need to understand what patients look for most in their contact lenses. Comfort is often a top priority, and patients need a safe space to discuss any discomfort they experience with their current lenses.

Research indicates that a significant percentage of patients hesitate to discuss comfort issues with their ECPs. Some patients may feel embarrassed or believe that discomfort is a normal part of wearing contact lenses.

SHERIDAN, WYOMING – November 9, 2024 – In a significant advancement for healthcare diagnostics, bioMérieux, a world leader in in vitro diagnostics, announces the launch of VIDAS® VITAMIN B12 TOTAL, a groundbreaking automated test designed to revolutionize the detection and management of vitamin B12 deficiency. This innovative test, which received CE marking, offers a rapid and efficient method for measuring vitamin B12 concentration in human serum or plasma, providing healthcare professionals with a critical tool for accurate diagnosis and timely treatment.

SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – Alcon, a global leader in eye care dedicated to helping people see brilliantly, presented its latest innovations and clinical data at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company showcased advancements in glaucoma therapy, retina surgery, and dry eye treatment, demonstrating its commitment to improving patient outcomes and streamlining surgical workflows.

Voyager™ DSLT: Revolutionizing Glaucoma Treatment

Alcon's latest innovation for glaucoma therapy, the Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) device, was a highlight of the event. This groundbreaking technology offers a first-line treatment option for glaucoma patients, eliminating the need for a gonio lens or manual aiming required for traditional Selective Laser Trabeculoplasty (SLT).

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline.  The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development.

Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

Dupixent Continues its Impressive Growth Trajectory

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues.

"We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

SHERIDAN, WYOMING – November 7, 2024 – Abbott, a global healthcare leader, is proud to announce the formation of Team Abbott, a worldwide community of runners united by their passion for health and fitness.  This initiative underscores Abbott's commitment to helping people live their best lives through the power of good health.

The inspiration behind Team Abbott stems from the recognition that marathons, while individual races, are ultimately a team sport. "Ask anyone who has run one and they’ll tell you: Marathons are a team sport," says an Abbott spokesperson. "Literally speaking, no, marathons can’t be relayed by a team of athletes, nor are they won by team organizations. But the process of training to run 26.2 miles, and attaining the health needed to do so, is a team effort."

SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens.

A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.

SHERIDAN, WYOMING – November 7, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game.

The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.  

"We knew as a leader in diagnostics and testing we had to do something powerful to draw in donors," said Abbott Chairman and CEO Robert Ford. "What better way to inspire people to donate than tapping into rivalries between Big Ten schools and offering up a friendly competition.”

SHERIDAN, WYOMING – November 7, 2024 – The world of marathon running has expanded with the addition of the TCS Sydney Marathon presented by Asics to the Abbott World Marathon Majors (AWMM). Starting in 2025, Sydney will join the prestigious ranks of Tokyo, Boston, London, Berlin, Chicago, and New York in hosting one of the world's most renowned marathons.

This exciting development not only adds a new race to the AWMM series but also brings the Southern Hemisphere into the fold, offering runners a unique opportunity to compete in a world-class marathon in a stunning location. The inaugural Sydney Marathon as part of the AWMM is scheduled for August 31, 2025, and anticipation is already building.

"We cannot wait to see our community embrace this race and start planning their visits to run the streets of one of the finest cities in the world,” said AWMM CEO Dawna Stone. "Runners, your Sydney star awaits.”

SHERIDAN, WYOMING – November 7, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

In addition, Abbott has received U.S. Food and Drug Administration (FDA) clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, further enhancing cardiac mapping capabilities for both PFA and radiofrequency (RF) ablation procedures.